Oruka Therapeutics, Inc. (ORKA)

Oruka Therapeutics, Inc. (ORKA) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $5.2B; returns 1 day -1.2%, 1 week +11.4%, 1 year +195.4%.

Oruka Therapeutics, Inc. (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company focused on engineering and developing novel monoclonal antibody therapeutics for chronic skin, inflammatory, and immunology (I&I) conditions, primarily targeting plaque psoriasis (PsO), psoriatic arthritis, and hidradenitis suppurativa.

Groups ORKA belongs to

• Biotechnology
• Biopharmaceutical
• Clinical Stage Biopharma
• Healthcare
• Monoclonal Antibodies
• Autoimmune Diseases
• Biologics
• Dermatology
• Antibody Therapeutics
• Chronic Inflammatory Diseases
• Clinical Stage
• Clinical Stage Biotech
• Life Sciences

ORKA financial model: income statement, cash flow and balance sheet